Agger nasi mucocele cause nasolacrimal duct obstruction and chronic dacryocystitis: clinical profile, management and outcome

Athanasios Saratziotis, Claudia Zanotti, Jiannis Hajiioannou, Enzo Emanuelli

SUMMARY

Epiphora is the first symptom of acquired nasolacrimal duct obstruction (NLDO), which may be due to various causes, including paranasal sinususes and tumours of the nasal cavity. A 28-year-old male patient presented chronic dacryocystitis with left-sided epiphora. Endoscopically, a bulging of the lateral nasal wall at the left-sided agger nasi area was noted. Imaging studies (CT and MRI) revealed a left-sided giant agger nasi mucocele. An endonasal endoscopic dacryocystorhinostomy (DCR) was performed in order to address dacryocystitis, which was treated with catheterisation, without the disease being resolved. Diagnosis of postsaccal NLDO was made by clinical examination, including lacrimal irrigation, fluorescein tests (Jones I and II tests), as well as probing of the canaliculi with a blunt probe up to bony contact with the lacrimal sac fossa, performed by an ophthalmologist.

TREATMENT

Under general anaesthesia, an endonasal endoscopic dacryocystorhinostomy (DCR) using a drill was performed. Through a monitor screen connected to a rigid nasal fibrotic endoscope and by using antrum curette and microdebrider, agger nasi cell was opened and a contained mucocele was removed, in combination with a left anterior ethmoidectomy. There was no evidence of macroscopic erosion of the bone surrounding the mucocele. Then, intraoperative irrigation was performed by an ophthalmologist to investigate the functionality of the nasolacrimal duct (NDL). A high degree of post-saccal stenosis was still present, even after removal of the mucocele, probably due to longstanding obstruction causing formation of plug and the extensive fibrosis within the nasolacrimal sac and/or the nasolacrimal duct. After completing all endonasal procedures, left anterior ethmoidectomy and sphenoid sinusitis were performed. The lacrimal bone anterior to the lacrimal sac fundus was removed with cutting drill, microdebrider in association with Kerrison punch without flap (Saratziotis et al). Temporary silicone stenting of the nasolacrimal duct system was passed through both upper and lower canaliculi and fixed in the nose (figure 2E). No postoperative complications occurred (figure 2F). Oral antibiotic therapy was initiated on the day of surgery and continued for 5 days. The patient was discharged the next day.

OUTCOME AND FOLLOW-UP

Lacrimal duct system irrigation was performed by an ophthalmologist once a week during the first month, two times a month during the second month.
Intranasal diseases as well as the role of anatomical variations should be included in the differential diagnosis of NLDO as in our case. Acquired NLDO caused by agger nasi mucocele was not reported in the literature before now and can be treated successfully with an endoscopic DCR procedure simultaneously.

**DISCUSSION**

The agger nasi is the most anterior ethmoidal air cell cell. Usually the incidence of the presence of agger nasi cells is more than 80%\(^5\); some authors report an even higher incidence of 98.5%. Furthermore, agger nasi cells are close to the lacrimal sac in 53% of patients and should be removed during DCR surgery.\(^6\) If present, it can usually be seen on the CT scan anterior to the middle turbinate.\(^5\) Because the agger nasi cell is the key to the frontal recess, the surgical approach is to open the agger nasi cell first and establish this as the key landmark for the frontal recess dissection if necessary, and for the lateral wall in concomitance with the uncinate process.\(^9\) These anatomical structures are the key for the proper access to the nasolacrimal drainage system.\(^10\)

Mucoceles are cyst-like paranasal sinus lesions lined with respiratory mucosa of pseudostratified columnar epithelium. Possible causes of an agger nasi mucocele include trauma, previous surgery, chronic sinusitis or congenital abnormalities or tumours. The ethmoid and frontal sinuses are common sites of paranasal sinus mucocele development, while the maxillary and sphenoid sinuses are relatively uncommon locations.\(^2\) Given that there was no history of previous trauma, paranasal surgery or symptoms of chronic sinusitis in this patient, the cause of mucocele formation is unclear. CT scan should be considered as one of the diagnostic methods of choice.

The highest incidence occurs in the frontal sinus (60%), followed by the ethmoid sinus (30%) and the maxillary sinus (10%). Sphenoid sinus mucoceles are very rare and are found in less than 1% of all cases.\(^11\) When evaluating a patient with acquired NLDO, the physician should consider evaluation for concomitant nasal and sinus disease.

There are studies that report association between radiologic evidence of sino-rhinologic disorders and lacrimal outflow obstruction and rhinologic abnormality in 87% and 63% of patients, respectively.

Their combination may also produce disease of the lateral nasal wall as the cause of dacyrocystitis.\(^12\)\(^13\) There are some reports in international literature on the presence of mucocele of agger nasi, but this is the first case we know, in which it is observed to be causing epiphora, dacyrocystitis and stenosis.\(^2\)

By means of an endoscopic endonasal approach, any intranasal or paranasal pathology can be treated simultaneously and a superior cosmetic result without any use of a cutaneous incision is achieved. Time to stent removal may range from 4–6 weeks to 2–3 months postoperatively. The success of DCR depends on the creation of an adequate space anterior to the common canaliculi and upper segment of the lacrimal sac, which is necessary to prevent adhesion and scarring at the site of rhinostomy.\(^14\) However, when there is a neighbouring agger nasi cell in the lacrimal bone, the endoscopic approach is indicated.\(^15\)

Ager nasi mucocele with expansion in the lacrimal bone is a rare occurrence; however, it carries a risk of major complications (local infection, orbital cellulitis, dacyrocystitis, necrosis, etc.). The evolution of the mucocele can be heavy and the emergency surgery is considered as the definitive treatment. Our differential

---

**Figure 1** Paranasal sinus CT sections. (A) Height of the evaluated agger nasi in coronal section. (B) Width of evaluated agger nasi in an axial section. T2 MRI scan with gadolinium of paranasal sinus. (C) Coronal contrast enhanced. (D) Axial contrast enhanced.

**Figure 2** (A) Endoscopic endonasal localisation of the large area of the first ethmoid cell. (B) Opening cleaning and removing agger nasi cell walls. (C) Agger nasi: internal dome and wall of the (D) localisation and removal of the tear bone. (E) Performing dacracycstorhinostomy. (F) Postoperative view after 2-year follow-up.
diagnosis of the NLDO with epiphora should consider endonasal causes also. Identification and recognition of rare ethmoidal causes, like agger nasi mucocele entity, may facilitate timely intervention and can be treated successfully with a simultaneous endoscopic DCR procedure.

**Learning points**

- Nasoendoscopic evaluation is essential in the management of epiphora due to nasolacrimal duct obstruction, as intranasal condition such as agger nasi mucocele could be the cause.
- When the cause of epiphora is due to intranasal causes, endonasal access treatment is also indicated.
- CT scan of the head is necessary to carry out when chronic dacryocystitis with epiphora persist for a long time.
- Teamwork and close cooperation between ophthalmologists and ENT surgeons in the management of the disorders of the lacrimal system lead to high success rates.

**Contributors**

AS, CZ, JH and EE contributed to planning to conception and design acquisition of data drafting the work and final approval of the version to be published.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient consent for publication**

Obtained.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**ORCID ID**

Athanasios Saratziotis http://orcid.org/0000-0002-2393-4012

**REFERENCES**


